psoriasis: An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
518 |
4. Check minimum number of eventsNone |
518 |
5. Include endpointsNone |
518 |
6. Filter based on genotype QC (FinnGen only) |
518 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L40
- Name in latin
- Psoriasis guttata
Similar endpoints
↥List of similar endpoints to
Guttate psoriasis
based on the number of shared cases.
Similar with more cases:
- Psoriasis
- Papulosquamous disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3699 | 2116 | 1568 |
| Only index persons | 3553 | 2064 | 1489 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.06 | 0.04 |
| Only index persons | 0.07 | 0.08 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 41.77 | 41.62 | 41.86 |
| Only index persons | 41.40 | 41.48 | 41.29 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 518 | 320 | 198 |
| Unadjusted period prevalence (%) | 0.10 | 0.11 | 0.09 |
| Median age at first event (years) | 46.58 | 44.06 | 50.65 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 466
- Matched controls
- 4658
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D05AX52
ATC
calcipotriol, combinations; topical
195.0
323.0
321
52
L40.4
ICD-10 Finland
Guttate psoriasis
4503599627370496.0
323.0
460
*
L40.0
ICD-10 Finland
Psoriasis vulgaris
1243.5
323.0
331
9
D05AX02
ATC
calcipotriol; topical
137.0
230.1
234
34
D07XC01
ATC
betamethasone, combinations; topical
24.7
168.9
263
232
D07AC01
ATC
betamethasone; topical
13.2
133.6
364
989
D05BB02
ATC
acitretin; oral
108.8
125.3
133
17
E0000UV
ATC
NA
12.0
119.6
380
1251
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
+∞
111.0
102
*
D05AX03
ATC
calcitriol; topical
140.1
104.2
108
10
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
15.9
99.4
175
170
E000001
ATC
NA
8.8
94.2
258
574
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
95.1
84.8
92
12
L40.5
ICD-10 Finland
Arthropathic psoriasis
960.6
84.3
80
*
L40.9
ICD-10 Finland
Psoriasis, unspecified
152.3
84.2
87
7
D07AC13
ATC
mometasone; topical
7.2
83.6
284
826
D07AD01
ATC
clobetasol; topical
8.9
81.0
203
371
L40
ICD-10 Finland
Psoriasis
96.6
80.3
87
11
D07AB08
ATC
desonide; topical
9.0
65.8
156
247
D07AB02
ATC
hydrocortisone butyrate; topical
5.8
65.5
262
850
M07.3
ICD-10 Finland
Other psoriatic arthropathies
606.4
55.8
54
*
E000002
ATC
NA
7.5
54.3
144
262
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
+∞
47.7
45
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
8.2
45.8
111
172
TQW80
NOMESCO Finland
Local dermatologic skincare
21.0
42.8
64
35
E000003
ATC
NA
10.5
42.5
87
100
D02AE01
ATC
carbamide; topical
9.0
42.3
95
129
S91
ICPC
Psoriasis
69.2
38.8
44
7
D02AX
ATC
Other emollients and protectives
11.9
32.6
61
58
D05AA
ATC
Tars
94.5
32.2
35
*
E000007
ATC
NA
7.8
31.6
76
113
L40.8
ICD-10 Finland
Other psoriasis
118.1
31.1
33
*
134
Kela drug reimbursment
General erythroderma
322.3
30.2
30
*
L04AB04
ATC
adalimumab; parenteral
23.5
28.8
41
19
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
10.8
28.6
56
58
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
5.1
27.5
94
219
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
+∞
24.2
23
*
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
+∞
21.0
20
*
L04AC05
ATC
ustekinumab; parenteral
219.4
20.7
21
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
5.6
20.5
62
124
XQ848
NOMESCO Finland
Dermatological photography
12.6
19.1
34
29
E000006
ATC
NA
4.9
19.0
65
149
L04AC10
ATC
secukinumab; parenteral
+∞
17.8
17
*
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
16.8
16
*
D07AA02
ATC
hydrocortisone; topical
3.1
15.1
92
345
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.8
15.0
108
451
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.5
14.5
134
644
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
9.6
14.4
29
32
D07XB01
ATC
flumetasone, combinations; topical
29.3
13.0
17
6
H02AB06
ATC
prednisolone; systemic
2.1
12.6
229
1485
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
8.0
12.6
28
37
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
13.9
12.0
20
15
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.9
11.9
50
140
A07EC01
ATC
sulfasalazine; oral, rectal
3.6
11.9
54
162
D09AB01
ATC
zinc bandage without supplements; topical
8.5
11.7
25
31
L04AD01
ATC
ciclosporin; systemic
8.7
11.4
24
29
L04AB01
ATC
etanercept; parenteral
13.1
11.2
19
15
J01FF01
ATC
clindamycin; systemic
2.2
11.2
143
790
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
+∞
10.5
10
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.3
10.2
52
171
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
10.2
190
1216
L04AA01
ATC
[U] ciclosporin; systemic
9.4
10.1
20
22
L04AC16
ATC
guselkumab; systemic
+∞
9.4
9
*
377
Kela drug reimbursment
Apremilast and dimethyl fumarate (psoriasis)
+∞
9.4
9
*
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.9
8.9
55
206
WQ066
NOMESCO Finland
NA
91.7
8.4
9
*
L04AC18
ATC
risankizumab; parenteral
+∞
8.4
8
*
L04AC13
ATC
ixekizumab; parenteral
+∞
8.4
8
*
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.8
7.8
199
1384
RJ411
NOMESCO Finland
NA
15.3
7.7
12
8
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
3.2
7.7
40
134
A46
ICD-10 Finland
Erysipelas
2.4
7.4
65
297
Z71.8
ICD-10 Finland
Other specified counselling
1.9
7.4
120
714
M54.5
ICD-10 Finland
Low back pain
1.8
7.3
156
1020
M07.2*L40.5
ICD-10 Finland
Psoriatic spondylitis
+∞
7.3
7
*
D05AX05
ATC
tazarotene; topical
+∞
7.3
7
*
M07.0
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
7.3
7
*
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
7.5
7.2
16
22
SPAT1263
SPAT
Sampling
1.7
7.2
200
1415
RJ421
NOMESCO Finland
NA
20.4
7.2
10
5
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.6
6.9
48
195
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.2
6.6
64
308
S18
ICPC
Laceration/cut
1.7
6.5
177
1236
L04AA32
ATC
apremilast; oral
+∞
6.3
6
*
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
1.6
6.1
214
1592
J01DB01
ATC
cefalexin; oral
1.8
6.1
380
3310
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.0
6.1
86
482
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
14
20.29
34.67
2.0
1.1
7.5
10.0
ug/l
1.31
27
14
58
117
5.46
27.94
1.5
1.6
1.0
0.0
iu/ml
—
10
21
323
2012
2.61
24.28
12.6
5.4
28.6
28.6
%
0.02
313
1891
319
1990
2.57
23.67
12.1
5.1
57.4
56.8
%
0.45
311
1879
357
2420
2.53
21.06
13.8
8.2
4.1
4.0
e9/l
0.28
331
2120
414
3148
2.57
16.86
5.8
3.7
12.1
10.7
mm/h
1.25
390
2906
414
3166
2.53
16.33
10.1
6.9
77.8
76.9
u/l
0.14
393
2972
165
970
2.03
11.83
1.7
1.6
—
—
—
0
0
236
1680
1.74
8.65
2.6
2.2
75.5
75.4
nmol/l
0.01
216
1524
164
1096
1.73
7.26
4.9
4.0
21.8
10.1
mg/mmol
0.67
118
684
25
76
3.41
7.05
4.7
3.6
3.9
4.3
e9/l
0.47
25
76
25
78
3.32
6.78
4.8
4.2
57.5
57.7
%
0.02
25
78
198
1423
1.63
6.52
3.2
3.0
33.7
32.1
u/l
0.25
188
1357
151
1022
1.67
6.24
2.8
2.4
336.7
6404.3
umol/l
3.93
134
908
477
4335
2.27
6.16
18.6
12.0
17.7
21.4
mg/l
2.04
395
3343
194
1405
1.61
6.10
4.1
2.9
—
—
—
0
0
245
1875
1.58
6.10
6.2
6.3
1.2
1.2
mmol/l
0.29
205
1577
156
1074
1.65
6.00
3.8
2.7
0.3
0.4
e6/l
0.47
117
794
268
2109
1.56
5.81
5.7
5.9
10.3
11.3
umol/l
0.85
253
2000
285
2324
1.50
4.92
4.8
4.5
6.6
6.6
mmol/l
0.01
265
2138
116
778
1.63
4.84
1.4
1.3
20.4
32.8
iu/ml
0.78
26
250
212
1633
1.50
4.79
5.3
4.5
35.8
36.3
g/l
0.77
198
1542
90
571
1.70
4.64
1.8
1.8
—
—
—
0
0
72
429
1.79
4.62
6.6
6.7
103.6
104.1
mmol/l
0.35
72
418
61
348
1.85
4.50
1.9
2.2
0.2
0.2
g/l
0.30
53
326
15
44
3.48
4.50
1.1
1.1
—
—
—
0
0
25
101
2.55
4.36
2.2
1.6
—
—
—
0
0
99
658
1.62
4.25
1.9
1.7
1003.9
1201.9
nmol/l
1.45
79
509
215
1694
1.46
4.20
5.5
5.6
1.2
1.2
mmol/l
0.58
194
1536
94
622
1.62
4.11
2.4
1.8
1.6
1.4
%
1.61
81
559
258
2113
1.44
4.06
4.3
3.3
0.0
0.0
estimate
0.50
59
398
93
617
1.62
4.02
3.0
2.5
1.1
1.0
e6/l
0.12
56
337
442
4033
1.65
4.00
18.7
10.8
87.7
86.0
ml/min/173m2
0.88
395
3286
465
4302
1.79
3.98
18.4
13.4
139.4
139.7
mmol/l
1.36
451
4190
192
1493
1.45
3.96
2.2
1.9
96.5
96.4
pmol/l
0.01
115
796
255
2090
1.43
3.96
6.1
4.5
0.0
0.0
estimate
0.00
62
413
253
2074
1.43
3.91
4.3
3.3
0.0
0.0
estimate
0.00
56
407
465
4318
1.75
3.71
18.5
13.5
4.0
4.0
mmol/l
0.03
449
4191
89
596
1.60
3.69
2.7
3.2
0.8
0.8
mmol/l
0.02
78
561
107
751
1.54
3.62
1.4
1.3
1.7
11.4
u/ml
3.86
44
314
46
259
1.85
3.56
1.9
1.6
—
—
—
0
0
53
315
1.76
3.45
4.6
3.4
2.1
1.8
mmol/l
0.22
44
247
21
88
2.44
3.44
2.1
1.3
—
—
—
0
0
87
591
1.57
3.40
3.0
2.7
2.8
2.7
e6/l
0.05
52
315
82
550
1.58
3.38
2.6
2.2
2.5
2.4
g/l
1.01
76
504
130
965
1.46
3.34
2.7
2.0
3.4
3.0
mg/l
1.08
116
838
18
71
2.59
3.33
2.2
1.5
6443.7
19313.8
e6/l
0.87
12
51
30
151
2.05
3.22
2.2
1.9
—
—
—
0
0
16
62
2.63
3.07
1.1
1.1
—
—
—
0
0
148
1143
1.41
3.04
2.1
2.0
187.9
233.1
u/l
0.24
140
1073
341
3022
1.38
2.95
3.9
2.9
56.4
43.5
u/l
1.76
315
2865
11
35
3.19
2.94
1.3
1.1
—
—
—
0
0
485
4609
1.82
2.87
18.5
9.1
29.6
26.7
u/l
1.56
475
4468
84
598
1.48
2.64
2.7
2.2
12.1
14.1
umol/l
1.38
78
547
7
15
4.71
2.60
1.0
1.1
1317.1
1812.8
miu/ml
—
7
15
63
423
1.56
2.60
14.9
19.1
1.2
1.3
inr
—
10
62
13
50
2.64
2.55
3.2
2.7
4.3
4.0
mmol/l
0.78
13
50
13
50
2.64
2.55
3.2
2.7
104.5
105.4
mmol/l
0.24
13
50
115
876
1.40
2.52
1.6
1.5
19.8
21.1
nmol/l
0.48
107
765
157
1263
1.35
2.46
3.3
2.4
52.7
54.9
u/l
0.48
143
1180
15
64
2.38
2.41
1.8
1.4
—
—
—
0
0
56
376
1.55
2.33
5.2
3.0
—
—
—
0
0
18
85
2.16
2.31
1.7
1.8
—
—
—
0
0
57
386
1.54
2.28
1.7
2.0
348.6
372.7
nmol/l
0.42
49
357
94
705
1.41
2.25
3.5
3.6
416.2
375.9
ng/l
0.05
64
494
71
507
1.46
2.21
2.8
2.3
20.6
24.3
%
1.17
60
440
18
87
2.11
2.19
1.7
1.8
—
—
—
0
0
502
4862
2.05
2.18
29.9
17.7
135.5
136.4
g/l
0.68
497
4808
37
228
1.67
2.18
3.8
3.2
5.2
5.1
kpa
0.47
32
218
25
137
1.87
2.17
1.3
1.1
—
—
—
0
0
90
675
1.40
2.16
2.1
1.9
—
—
—
0
0
45
293
1.59
2.14
3.8
3.7
1.2
1.2
mmol/l
0.62
40
252
25
138
1.85
2.13
1.3
1.1
—
—
—
0
0
57
393
1.51
2.11
5.8
8.5
5.1
5.1
kpa
0.12
51
376
57
393
1.51
2.11
5.8
8.5
12.8
12.4
kpa
0.13
51
378
98
750
1.38
2.08
2.1
2.1
—
—
—
0
0
344
3127
1.30
2.08
3.4
3.3
—
—
—
0
0
14
63
2.26
2.02
1.3
1.9
—
—
—
0
0
25
142
1.80
1.96
2.1
1.8
—
—
—
0
0
132
1070
1.31
1.92
1.9
1.6
1.4
1.4
mmol/l
0.02
120
924
120
960
1.33
1.91
1.5
1.7
1.2
1.0
mg/l
0.20
93
723
56
394
1.47
1.90
5.9
8.6
0.7
1.1
mmol/l
0.21
41
311
137
1118
1.31
1.90
4.7
3.5
0.0
0.0
estimate
0.50
60
404
13
59
2.23
1.85
1.1
1.3
—
—
—
0
0
120
966
1.32
1.83
2.3
2.2
—
—
—
0
0
359
3307
1.28
1.82
4.0
3.9
14.6
14.6
pmol/l
0.02
324
3037
9
35
2.60
1.81
1.4
1.5
—
—
—
0
0
34
217
1.61
1.78
3.5
3.3
1.6
1.7
mmol/l
0.01
26
162
53
374
1.46
1.78
3.5
2.3
26.1
162.6
u/l
0.53
47
311
18
95
1.93
1.77
2.7
2.3
292.2
120.9
ug/min
0.29
11
55
174
1477
1.27
1.76
4.1
3.3
85.1
37.8
ng/l
0.45
111
912
35
226
1.59
1.76
1.5
1.4
—
—
—
0
0
420
3958
1.32
1.72
4.9
4.6
1.8
2.1
mu/l
0.49
385
3679
10
213
0.46
1.69
5.1
1.8
1.4
3.6
mg/l
—
5
153
190
1636
1.25
1.69
4.8
3.4
—
—
—
0
0
223
1958
1.24
1.67
3.4
2.8
99.9
108.6
ug/l
0.32
211
1834
27
166
1.66
1.65
1.2
1.4
—
—
—
0
0
24
143
1.71
1.64
1.4
1.9
—
—
—
0
0
7
26
2.71
1.58
1.3
1.2
—
—
—
0
0
6
20
3.02
1.58
1.8
3.6
73.2
91.3
nmol/l
—
6
20
222
1957
1.24
1.58
4.1
4.0
—
—
—
0
0
432
4101
1.32
1.58
4.5
4.0
6.0
5.8
mmol/l
1.13
393
3802
100
802
1.31
1.57
1.8
1.6
424.5
433.8
pmol/l
0.18
88
695
5
15
3.35
1.52
1.4
1.3
—
—
—
0
0
7
27
2.61
1.52
1.1
1.1
325.0
143.2
iu/ml
—
7
27
6
21
2.88
1.51
6.3
3.0
418.0
546.2
u/ml
—
6
21
9
37
2.46
1.48
1.2
1.2
—
—
—
0
0
53
392
1.39
1.41
1.7
1.7
—
—
—
0
0
9
40
2.27
1.40
1.1
1.7
—
—
—
0
0
9
40
2.27
1.40
1.1
2.1
—
—
—
0
0
9
40
2.27
1.40
1.1
1.7
—
—
—
0
0
9
40
2.27
1.40
1.1
1.7
—
—
—
0
0
116
964
1.26
1.38
3.2
3.1
1826.1
1190.3
ng/l
0.32
100
818
16
90
1.80
1.34
1.1
1.2
—
—
—
0
0
15
83
1.83
1.32
1.5
2.0
—
—
—
0
0
29
193
1.53
1.32
1.5
1.6
—
—
—
0
0
60
460
1.34
1.30
2.5
2.5
6.7
8.7
umol/l
0.62
51
395
151
1304
1.22
1.27
2.5
3.0
2.3
2.4
mmol/l
1.12
130
1167
19
115
1.68
1.26
1.4
2.0
1.9
6.3
iu/l
—
7
44
14
240
0.57
1.26
2.5
2.5
14.4
43.0
u/ml
1.94
14
231
51
387
1.35
1.19
1.7
1.7
—
—
—
0
0
35
249
1.44
1.18
2.6
3.0
174.9
175.4
ng/l
0.00
29
220
0
35
0.00
1.15
0.0
1.5
—
20.6
—
0
30
37
268
1.41
1.14
1.3
1.3
—
—
—
0
0
16
96
1.69
1.11
1.6
1.2
—
—
—
0
0
403
3842
1.22
1.10
6.8
5.1
39.9
39.2
mmol/mol
0.70
376
3621
7
33
2.14
1.06
1.1
1.4
—
—
—
0
0
18
114
1.60
1.04
1.0
1.3
—
2.6
—
0
14
5
22
2.28
1.03
1.2
1.4
5.5
6.5
mmol/l
—
5
22
9
47
1.93
1.02
1.1
1.9
—
—
—
0
0
9
48
1.89
1.01
1.4
1.7
—
—
—
0
0
440
4246
1.24
0.98
5.3
4.0
4.7
4.7
mmol/l
0.15
408
4001
5
23
2.19
0.98
1.6
1.8
—
—
—
0
0
15
92
1.65
0.98
1.3
1.3
—
—
—
0
0
18
116
1.57
0.98
1.0
1.3
—
7.3
—
0
20
7
36
1.96
0.97
2.3
2.2
—
—
—
0
0
11
62
1.79
0.95
1.5
1.1
—
—
—
0
0
9
52
1.74
0.92
2.4
1.7
—
—
—
0
0
22
151
1.48
0.92
1.5
1.6
—
—
—
0
0
52
646
0.78
0.91
2.7
2.8
0.6
0.7
ug/l
0.29
34
393
13
79
1.66
0.88
1.2
1.1
0.3
1.7
u/ml
—
5
28
39
300
1.32
0.87
2.5
2.3
7.2
8.0
ug/l
0.18
31
270
17
112
1.54
0.86
4.9
3.9
4.0
3.9
mmol/l
0.50
17
104
6
31
1.95
0.84
1.7
3.2
—
—
—
0
0
11
176
0.62
0.81
1.5
1.4
—
—
—
0
0
11
176
0.62
0.81
1.5
1.4
—
—
—
0
0
30
225
1.35
0.80
3.1
2.2
5593.8
3142.0
u/l
—
10
105
11
175
0.62
0.79
1.5
1.4
—
—
—
0
0
11
175
0.62
0.79
1.5
1.4
—
—
—
0
0
18
123
1.48
0.78
1.2
1.3
—
—
—
0
0
106
928
1.18
0.77
4.5
3.5
1.0
1.0
kg/l
0.01
23
125
6
34
1.77
0.76
1.0
1.1
—
—
—
0
0
18
124
1.47
0.76
1.0
1.3
—
2.3
—
0
6
13
196
0.65
0.75
2.5
1.9
—
—
—
0
0
5
24
2.09
0.74
1.0
1.8
—
—
—
0
0
5
24
2.09
0.74
1.0
1.8
—
—
—
0
0
5
24
2.09
0.74
1.0
1.8
—
—
—
0
0
5
24
2.09
0.74
1.0
1.8
—
—
—
0
0
422
4085
1.18
0.74
4.8
3.6
1.4
1.3
mmol/l
1.07
390
3828
9
55
1.65
0.74
1.4
1.4
—
—
—
0
0
20
142
1.42
0.73
1.8
1.8
—
—
—
0
0
5
25
2.01
0.73
2.2
1.9
—
1224630.0
—
0
5
7
39
1.81
0.72
1.0
1.1
—
—
—
0
0
9
56
1.62
0.72
1.4
1.4
—
—
—
0
0
9
56
1.62
0.72
1.4
1.4
—
—
—
0
0
118
1049
1.16
0.72
1.3
1.2
0.8
2.0
u/ml
1.49
29
302
10
61
1.65
0.69
2.3
1.6
—
—
—
0
0
13
86
1.52
0.66
1.0
1.3
—
1.0
—
0
5
5
28
1.79
0.66
1.4
1.3
3.4
1.9
mmol/l
—
5
28
5
30
1.67
0.61
16.8
9.3
0.4
0.6
mmol/l
—
5
30
13
89
1.47
0.58
1.0
1.2
—
—
—
0
0
8
55
1.46
0.56
1.5
1.4
—
—
—
0
0
6
37
1.63
0.55
3.0
3.8
—
—
—
0
0
11
74
1.50
0.53
1.3
1.2
—
—
—
0
0
11
74
1.50
0.53
1.3
1.2
—
—
—
0
0
9
63
1.44
0.52
1.7
2.7
—
1032.0
—
0
6
16
214
0.74
0.52
1.5
1.4
—
—
—
0
0
6
40
1.51
0.51
1.2
1.0
—
—
—
0
0
10
145
0.68
0.51
1.0
1.1
—
6.3
—
0
21
6
41
1.47
0.50
1.5
2.9
22.7
51.3
u/ml
—
6
41
17
128
1.34
0.48
1.3
1.9
100.4
90.3
%
1.14
17
122
14
188
0.74
0.47
1.5
1.5
—
—
—
0
0
32
267
1.21
0.43
5.2
3.6
131.9
76.1
ng/l
1.13
27
242
42
360
1.18
0.43
4.1
4.3
3.2
19.0
ug/l
0.73
32
294
5
31
1.62
0.43
1.2
1.8
—
—
—
0
0
8
56
1.44
0.42
1.5
1.4
—
—
—
0
0
8
56
1.44
0.42
1.5
1.4
—
—
—
0
0
5
32
1.57
0.42
1.2
1.2
—
—
—
0
0
10
70
1.44
0.42
1.1
1.3
—
—
—
0
0
440
4318
1.13
0.41
5.3
4.4
2.8
2.8
mmol/l
0.12
408
4040
5
33
1.52
0.41
1.4
1.2
—
0.1
u/ml
—
0
14
37
315
1.19
0.41
3.8
2.6
64.6
69.2
ml/min/173m2
0.44
21
135
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.0
—
—
—
0
0
53
466
1.15
0.40
4.5
4.1
30.5
31.6
%
0.33
34
323
5
34
1.48
0.40
1.2
2.0
—
—
—
0
0
10
71
1.42
0.39
2.3
1.6
—
—
—
0
0
5
35
1.43
0.39
1.6
1.8
—
—
—
0
0
80
878
0.89
0.38
3.8
4.1
25.3
20.7
%
0.92
31
378
14
108
1.30
0.35
1.4
3.3
—
2.1
—
0
16
6
45
1.34
0.34
1.0
1.2
—
—
—
0
0
51
455
1.13
0.33
14.0
5.9
—
—
—
0
0
430
4228
1.10
0.33
4.9
4.0
1.4
1.5
mmol/l
0.43
400
3971
29
249
1.17
0.31
1.1
1.0
—
—
—
0
0
21
175
1.21
0.30
1.3
1.4
214.4
251.2
miu/ml
—
10
88
10
75
1.34
0.30
1.4
1.1
—
—
—
0
0
7
55
1.28
0.30
1.6
1.6
—
—
—
0
0
28
242
1.17
0.28
1.3
1.3
35.0
25.9
iu/l
0.52
22
205
8
62
1.29
0.28
2.9
2.5
9.1
70.8
u/ml
—
8
57
9
116
0.77
0.27
1.4
1.8
39.3
37.9
g/l
—
9
105
8
64
1.25
0.27
1.1
1.1
131.0
116.9
%
—
8
59
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
95
1.27
0.26
2.5
3.1
0.3
0.4
u/ml
—
7
54
9
74
1.22
0.25
1.0
1.1
—
—
—
0
0
31
349
0.88
0.24
1.1
1.2
92.3
169.1
iu/ml
1.37
13
145
46
419
1.11
0.23
2.5
1.9
—
—
—
0
0
12
146
0.82
0.22
1.7
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
9.6
—
0
6
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
2.2
—
2.4
—
0
6
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
15
126
1.20
0.21
1.3
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
3.9
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
3.9
—
—
—
0
0
10
81
1.24
0.19
1.5
1.8
—
—
—
0
0
29
319
0.90
0.17
1.6
1.5
—
—
—
0
0
8
69
1.16
0.16
1.1
1.1
—
—
—
0
0
11
92
1.20
0.16
1.5
1.5
—
—
—
0
0
6
78
0.77
0.15
1.5
1.4
—
—
—
0
0
15
132
1.14
0.13
1.6
1.8
—
—
—
0
0
13
113
1.15
0.13
1.5
1.5
—
—
—
0
0
72
688
1.05
0.13
2.8
2.7
2.4
2.4
mmol/l
0.04
65
609
9
106
0.85
0.13
1.4
1.9
0.0
0.0
g/l
—
9
101
18
161
1.12
0.13
2.6
1.7
—
—
—
0
0
35
330
1.06
0.09
2.3
1.8
—
—
—
0
0
5
46
1.09
0.09
1.0
1.1
—
—
—
0
0
13
116
1.12
0.09
2.0
2.8
—
—
—
0
0
45
471
0.95
0.09
1.7
1.6
—
—
—
0
0
20
186
1.08
0.07
1.3
1.4
—
—
—
0
0
10
112
0.89
0.07
1.4
1.9
0.1
0.0
g/l
—
10
107
107
1092
0.97
0.06
4.4
4.4
1.4
2.1
ug/l
1.53
93
980
81
795
1.02
0.04
1.5
1.4
—
—
—
0
0
407
4081
0.99
0.02
20.6
12.4
39.2
40.5
%
1.66
299
3183
17
164
1.04
0.00
1.4
1.4
1.3
1.2
g/l
0.71
17
157
14
143
0.98
0.00
1.3
1.9
—
—
—
0
0
14
143
0.98
0.00
1.3
1.9
3.9
3.9
g/l
—
9
108
10
102
0.98
0.00
1.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
5
59
0.85
0.00
19.2
1.9
13.2
13.2
%
—
5
59
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
116.1
—
0
7
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
1.3
—
0
7
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
5
52
0.96
0.00
1.0
1.0
—
—
—
0
0
5
51
0.98
0.00
1.0
1.1
—
—
—
0
0
5
50
1.00
-0.00
1.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PSORI_GUTTATE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PSORI_GUTTATE | 1.255 [1.02, 1.54] | 0.032 |
| Birth year | 0.994 [0.99, 1.0] | 0.2 |
During the follow-up period (1.1.1998 — 31.12.2019), 164 out of 1925 females with L12_PSORI_GUTTATE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PSORI_GUTTATE | 1.695 [1.38, 2.08] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.01 |
During the follow-up period (1.1.1998 — 31.12.2019), 209 out of 1420 males with L12_PSORI_GUTTATE died.
Mortality risk
Mortality risk for people of age
years, who have L12_PSORI_GUTTATE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.107% | 0.352% |
| 5 | 0.745% | 1.989% |
| 10 | 1.799% | 4.954% |
| 15 | 3.345% | 9.073% |
| 20 | 5.875% | 14.936% |
Relationships between endpoints
↥Index endpoint: L12_PSORI_GUTTATE – Guttate psoriasis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data